Our multidisciplinary approach involves collaboration across schools, institutes and industries. From the bed to the bench and back,  USC Ginsburg IBT continues to be at the forefront of scientific discovery in advancing the field of biomedical engineering in the treatment of neurosensory diseases. Our physicians and scientists work closely together, bringing clinical challenges to the bench which spans the continuum of basic, translational and clinical research across all disciplines.

With a vast infrastructure and network, our research has led to the first FDA approved retinal prosthesis, Argus II, in the treatment of retinitis pigmentosa. In addition, our work in stem cell research has resulted in the development of synthetic cellular scaffolds for treatment of age-related macular degeneration (AMD) to be tested in upcoming human clinical trials. The results to date and new advances underway for neurosensory diseases are remarkable.

Translational Research In Vivo Core Facility

To advance our translational research efforts please visit our new Translational Research In Vivo Core Facility, which provides the infrastructure and services, state-of-the art imagine equipments to conduct preclinical studies.

Next, read about our Education.